Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NuBiyota LLC
Microbiome Offers Rich Pickings As Takeda Becomes Enterome's Second Big Pharma Crohn's Partner
Takeda's $50m+ deal for Enterome's EB8018 is based on a separate platform from that being used under the French company's collaboration with Johnson & Johnson.
Deals Of The Year: Cast Your Vote For Top Alliance Of 2017
It's time for In Vivo's10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.) First up, the top five picks for most significant strategic alliance of 2017.
Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar
Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijin.
China Embracing Microbiome Research Through Programs, Partnerships
NuBiyota is setting up a local presence to tap into China’s growing commitment to developing new therapeutics based on the microbiome, an area the country is increasingly supporting through central initiatives as part of a national precision medicine program, and where new partnerships are emerging.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.